Enanta内部人出售了9 000多股第5号股票,尽管季度损失和收入亏损,股票略有上升。 Enanta insiders sold over 9,000 shares Dec. 5 as stock rose slightly despite quarterly loss and revenue miss.

2025年12月5日,包括CEO Jay Luly、Scott Rottinghaus、Brendan Luu和Yat Sun Or在内的多个Enanta制药公司内幕人士共出售9 000多股股票,每股14.23美元,减少了他们的股份。 On December 5, 2025, multiple Enanta Pharmaceuticals insiders, including CEO Jay Luly, Scott Rottinghaus, Brendan Luu, and Yat Sun Or, sold a combined total of over 9,000 shares at $14.23 per share, reducing their stakes. 库存增加了0.51美元,以14.60美元结束,数量低于平均水平。 The stock rose $0.51 to close at $14.60, with below-average volume. 虽然Enanta公司的季度亏损每股0.87美元, 超过预期的0.26美元, 但收入却低于预期的15.13亿美元. Enanta reported a quarterly loss of $0.87 per share, beating estimates by $0.26, but revenue of $15.13 million fell short of forecasts. 该公司的重点是用于病毒感染和肝病的小分子药物,市场上限为4.2136亿美元,协商一致的“Moderate Buy”评级为20.33美元,目标是20.33美元。 The company, focused on small molecule drugs for viral infections and liver diseases, has a market cap of $421.36 million and a consensus "Moderate Buy" rating with a $20.33 target.